Parkinson's Disease Drugs Market - Segmented by Mechanism of Action and
Geography - Growth, Trends, and Forecast (2018 - 2023)" report
has been added to ResearchAndMarkets.com's offering.
The Parkinson's disease drugs market is expected to witness a CAGR of
6.2% during the forecast period, 2018-2023. The global Parkinson's
disease drug market has witnessed a remarkable growth in the recent
years, due to a large patient pool and increased diagnosis rates.
Recent Drug Approvals
Researchers are working to develop new and improved therapies for people
with Parkinson's disease (PD). There have been many drugs that have been
approved to treat Parkinson disease. In January 2015, the US FDA
approved an extended release formulation of levodopa/carbidopa.
Recently in January 2018, Adamas Pharmaceuticals Inc. has launched
Gocovri (amantadine extended-release capsules) for the treatment of
dyskinesia in people with Parkinson's, who are taking levodopa. This is
the first drug indicated specifically for dyskinesia, which is developed
with the long-term usage of levodopa.
These newly-approved drugs, with different formulations, are addressing
different unmet needs and are expected to drive the Parkinson disease
The other factors, which are also driving the market, include increasing
demand due to the higher prevalence of the disease, new entrants
expected to balance generic intrusion, and increasing use of the MAO-B
Generic Competition to Key Therapies - Restraining the Market
Europe Holds the Largest Share of the Market
Major Market Developments
Pfizer, the world's third-largest drug maker, announced that it is
ending research to discover new medications for Alzheimer's and
Parkinson's diseases, due to the high cost involved.
Adamas Pharmaceuticals Inc. launched Gocovri (amantadine
extended-release capsules) for the treatment of dyskinesia.
Merck & Co. Inc.
Impax Laboratories Inc.
Somerset Pharmaceuticals Inc.
Johnson & Johnson (Janssen)
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
10. The Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/629qdk/global?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180919005374/en/
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Nervous System Drugs
Source: Research and Markets